PMID- 36635351
OWN - NLM
STAT- MEDLINE
DCOM- 20230116
LR  - 20230301
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Jan 12
TI  - PDJ amplicon in triple negative breast cancer.
PG  - 618
LID - 10.1038/s41598-023-27887-8 [doi]
LID - 618
AB  - Amplification of chromosome 9p24.1 targeting PD-L1, PD-L2, and JAK2 (PDJ 
      amplicon) is present in subsets of triple negative breast cancers (TNBCs) and is 
      associated with poor clinical outcomes. However, the prevalence of PDJ+ TNBCs 
      varies extensively across studies applying different methods for interrogating 
      samples of interest. To rigorously assess the prevalence of PDJ amplicons in 
      TNBC, its prognostic value and whether it is enriched by chemotherapy, we 
      interrogated 360 TNBC samples including 74 surgical resections from patients 
      treated in the neoadjuvant setting, and tissue microarrays (TMAs) with 31 cases 
      from African American women and 255 resected non-metastatic cases, with a 3 color 
      fluorescence in situ hybridization (FISH) assay targeting the 9p24.1 PDJ 
      amplicon, 9q24.3, and 9q34.1. Samples with mean PDJ signal of > 4.5 copies, and 
      ratios of PDJ/9q24 >/= 2 and/or PDJ/9q34.1 >/= 2 were called amplified (PDJ+). 
      Correlative analyses included the association of tumor infiltrating lymphocytes 
      (TILs) with PDJ amplicons in TNBCs. In addition, we investigated intratumor copy 
      number of PDJ amplicons in PDJ+ and PDJ- TNBCs. Matched pre- and post-neoadjuvant 
      treatment biopsies were available from patients (n = 6) to evaluate the effects 
      of therapy on PDJ status. Our study provides a rigorous analysis of the 
      prevalence, distribution, and clinical correlatives of the PDJ amplicon in TNBC.
CI  - (c) 2023. The Author(s).
FAU - Roesler, Alexander S
AU  - Roesler AS
AD  - Department of Research, Mayo Clinic in Arizona, Scottsdale, AZ, USA.
AD  - School of Medicine, Duke University, Durham, NC, USA.
FAU - Malasi, Smriti
AU  - Malasi S
AD  - Department of Research, Mayo Clinic in Arizona, Scottsdale, AZ, USA.
FAU - Koslosky, Lori
AU  - Koslosky L
AD  - MetaSystems Group, Inc., Newton, MA, USA.
FAU - Hartmayer, Peter
AU  - Hartmayer P
AD  - MetaSystems Group, Inc., Newton, MA, USA.
FAU - Naab, Tammey J
AU  - Naab TJ
AD  - Department of Pathology, Howard University Hospital, Washington, DC, USA.
FAU - Carter, Jodi M
AU  - Carter JM
AD  - Departments of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 
      USA.
AD  - Departments of Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Zahrieh, David
AU  - Zahrieh D
AD  - Departments of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Hillman, David
AU  - Hillman D
AD  - Departments of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Leon-Ferre, Roberto A
AU  - Leon-Ferre RA
AD  - Departments of Oncology, Mayo Clinic, Rochester, MN, USA.
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Departments of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 
      USA.
FAU - Goetz, Matthew P
AU  - Goetz MP
AD  - Departments of Oncology, Mayo Clinic, Rochester, MN, USA.
FAU - Anderson, Karen S
AU  - Anderson KS
AD  - Division of Hematology-Oncology, Mayo Clinic in Arizona, Scottsdale, AZ, USA.
AD  - Biodesign Institute, Arizona State University, Tempe, AZ, USA.
FAU - Pockaj, Barbara A
AU  - Pockaj BA
AD  - Division of General Surgery, Section of Surgical Oncology, Mayo Clinic in 
      Arizona, Phoenix, AZ, USA.
FAU - Barrett, Michael T
AU  - Barrett MT
AD  - Department of Research, Mayo Clinic in Arizona, Scottsdale, AZ, USA. 
      barrett.michael@mayo.edu.
AD  - Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic 
      in Arizona, Scottsdale, AZ, USA. barrett.michael@mayo.edu.
LA  - eng
GR  - P50 CA116201/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230112
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Triple Negative Breast Neoplasms/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - B7-H1 Antigen/genetics
MH  - Neoadjuvant Therapy
MH  - Lymphocytes, Tumor-Infiltrating/pathology
MH  - Biomarkers, Tumor/genetics
PMC - PMC9837184
COIS- Author LK. and P.H. are employed by MetaSystems Group, Inc. (Newton, MA, USA), 
      and Author A.S.R., S.M., T.J.N., J.M.C.,D.Z., D.H., R.L.F., F.J.C., M.P.G., 
      K.S.A., B.A.P., and M.B. do not have any Competing-Interest.
EDAT- 2023/01/13 06:00
MHDA- 2023/01/17 06:00
PMCR- 2023/01/12
CRDT- 2023/01/12 23:18
PHST- 2022/09/12 00:00 [received]
PHST- 2023/01/10 00:00 [accepted]
PHST- 2023/01/12 23:18 [entrez]
PHST- 2023/01/13 06:00 [pubmed]
PHST- 2023/01/17 06:00 [medline]
PHST- 2023/01/12 00:00 [pmc-release]
AID - 10.1038/s41598-023-27887-8 [pii]
AID - 27887 [pii]
AID - 10.1038/s41598-023-27887-8 [doi]
PST - epublish
SO  - Sci Rep. 2023 Jan 12;13(1):618. doi: 10.1038/s41598-023-27887-8.